Lunasine

DB16223InvestigationalSmall molecule

Lunasine is under investigation in clinical trial NCT02709330 (ALS Reversals - Lunasin Regimen).

Mechanism: Pharmacologically active on Integrin beta-3, Histone acetyltransferase KAT2B, and Integrin alpha-V
Curator reviewed
Formula / weight: C₁₇H₂₂NO₃ · 288.366 g/mol (avg)
Also known as: (-)-lunasine · Lunasin · Lunasine, (-)-

Resolves to

Compound

Structure

InChIKeyGUIBZZYABLMRRD-CQSZACIVSA-NSMILESCOC1=CC=CC2=C1[N+](C)=C1O[C@H](CC1=C2OC)C(C)C

Targets

What you can answer from here — as of July 08, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lunasine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.